Qiagen N.V. (QGEN) Stock
QGEN Key Statistics
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
CEO: Jon Pratt. Company website
QGEN — Frequently Asked Questions
What is the QGEN stock price today?
Qiagen N.V. (QGEN) trades at $43.33, down 2.37% on the day, as of Sep 20, 2026 15:00 UTC.
What is Qiagen N.V.'s market cap?
Qiagen N.V. has a market capitalisation of $8.94B, calculated from the live QGEN share price and shares outstanding.
What is the P/E ratio of QGEN?
QGEN trades at a trailing P/E of 22.22, from earnings per share of $1.95 over the last twelve months.
How much revenue does Qiagen N.V. make?
Qiagen N.V. generated revenue of $2.10B over the trailing twelve months, which puts the stock at 4.25 times sales.
Does QGEN pay a dividend?
Yes. Qiagen N.V. pays a dividend yielding 0.53% on the current share price.
What is the 52-week range for QGEN?
QGEN has traded between $32.53 and $57.82 over the past 52 weeks, and the last price is 25.1% below that high.
Is Qiagen N.V. profitable?
Yes. Qiagen N.V. keeps 19.49% of revenue as net income over the trailing twelve months.
What is the analyst price target for QGEN?
Wall Street analysts rate QGEN Hold, with an average price target of $43.01, 0.7% below the current price.
What sector is Qiagen N.V. in?
Qiagen N.V. is classified under the Healthcare sector and the Medical - Diagnostics & Research industry, and is domiciled in NL.
Who is the CEO of Qiagen N.V.?
Jon Pratt is the chief executive of Qiagen N.V., which employs 5,500 people.
Where can I track QGEN in real time?
QFI Terminal shows QGEN with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See QGEN live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open QGEN in Terminal See plans